Pfizer and Astellas released positive Phase 3 data from their Embark trial demonstrating that combining Xtandi (enzalutamide) with leuprolide significantly improves overall survival for men with non-metastatic hormone-sensitive prostate cancer (nmHSPC) experiencing biochemical recurrence at high risk of metastasis. Xtandi monotherapy did not reach statistical significance for survival. The combination therapy marks the first androgen receptor inhibitor regimen to show a survival benefit in this population. Xtandi continues to be a major revenue driver for Astellas with robust sales growth.